SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the third quarter ended September 30, 2024, and provided recent business... Read More

Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company... Read More

Realigning resources to focus on clinical advancement of Selected TIL therapy Reducing employee headcount by approximately 60% Streamlining operations with cash runway expected to extend into 2Q 2026 SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with... Read More

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and... Read More

Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing success Product characterization and translational data support biological hypothesis... Read More

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business... Read More

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the... Read More

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The... Read More

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone... Read More

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor... Read More

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced with sadness that P. Joseph Campisi, Jr., Esq, the Company’s Chief Legal Officer, passed away on... Read More

SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer, will participate in the Piper... Read More

Promising preclinical data showcasing Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023 Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with initial clinical data expected mid-2024 Upsized IPO extends runway into Q2 2025 and supports advancement of pipeline through key milestones Further strengthened Scientific Advisory Board with appointment of internationally recognized... Read More

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the continued clinical advancement of TIDAL-01, Turnstone’s lead Selected TIL therapy, currently being evaluated in two Phase 1 trials Results also demonstrate the potential for a streamlined and rapid selection process and genetic... Read More

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the addition of Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Weber will work with... Read More

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced four posters reporting preclinical data for Turnstone’s Selected TIL therapies will be presented at the 38 th... Read More

Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programs Cash position expected to fund operations into second quarter of 2025 Two Phase 1 clinical trials of lead program, TIDAL-01, in several solid tumor Indications ongoing SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a... Read More